A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Naquotinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 01 Aug 2017 Status changed from recruiting to withdrawn prior to enrolment.
- 26 Jul 2017 Planned End Date changed from 1 Jan 2019 to 17 Nov 2016.
- 26 Jul 2017 Planned primary completion date changed from 4 Dec 2018 to 16 Nov 2016.